

Wright Medical Group, Inc.
Reconciliation of Net Sales to Net Sales Excluding the Impact of Foreign Currency
(dollars in thousands--unaudited)

	Three Months Ended		Nine Months Ended	
	September 30, 2011		September 30, 2011	
	International Net Sales	Total Net Sales	International Net Sales	Total Net Sales
Net sales, as reported	\$ 48,802	\$ 118,184	\$ 163,397	\$ 386,075
Currency impact as compared to prior period	(3,189)	(3,189)	(9,755)	(9,755)
Net sales, excluding the impact of foreign currency	<u>\$ 45,613</u>	<u>\$ 114,995</u>	<u>\$ 153,642</u>	<u>\$ 376,320</u>

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(in thousands, except per share data--unaudited)

	Three Months Ended		Nine Months Ended	
	September 30, 2011	September 30, 2010	September 30, 2011	September 30, 2010
Operating Income				
Operating income, as reported	\$ (23,104)	\$ 9,221	\$ 488	\$ 22,005
<i>Reconciling items impacting Gross Profit:</i>				
Non-cash, stock-based compensation	356	314	1,063	980
Cost of sales - restructuring	1,900	—	1,900	—
Employment matters ⁽¹⁾	99	—	99	—
Total	<u>2,355</u>	<u>314</u>	<u>3,062</u>	<u>980</u>
<i>Reconciling items impacting Selling, General and Administrative expenses:</i>				
Non-cash, stock-based compensation	1,715	2,261	5,083	7,700
U.S. governmental inquiries/DPA related	4,974	942	9,541	9,619
Employment matters ⁽¹⁾	1,783	—	1,783	—
Product liability provision	13,199	—	13,199	—
Total	<u>21,671</u>	<u>3,203</u>	<u>29,606</u>	<u>17,319</u>
<i>Reconciling items impacting Research and Development expenses:</i>				
Non-cash, stock-based compensation	150	492	542	1,500
Employment matters ⁽¹⁾	135	—	135	—
Total	<u>285</u>	<u>492</u>	<u>677</u>	<u>1,500</u>
<i>Other Reconciling Items:</i>				
Restructuring charges	12,132	134	12,132	1,139
Operating income, as adjusted	<u>\$ 13,339</u>	<u>\$ 13,364</u>	<u>\$ 45,965</u>	<u>\$ 42,943</u>
Operating income, as adjusted, as a percentage of net sales	<u>11.3%</u>	<u>11.0%</u>	<u>11.9%</u>	<u>11.3%</u>

(1) Costs associated with settlement of certain employment matters and the hiring of a new CEO.

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(in thousands, except per share data--unaudited)

	<u>Three Months Ended</u>		<u>Nine Months Ended</u>	
	<u>September 30, 2011</u>	<u>September 30, 2010</u>	<u>September 30, 2011</u>	<u>September 30, 2010</u>
Net Income				
Income before taxes, as reported	\$ (24,627)	\$ 7,376	\$ (9,061)	\$ 17,185
<i>Pre-tax impact of reconciling items:</i>				
Non-cash, stock-based compensation	2,221	3,067	6,688	10,180
U.S. governmental inquiries/DPA related	4,974	942	9,541	9,619
Deferred financing fees and transaction costs associated with Convertible Notes Tender Offer	—	—	4,099	—
Restructuring charges	14,032	134	14,032	1,139
Employment matters ⁽¹⁾	2,017	—	2,017	—
Product liability provision	13,199	—	13,199	—
Income before taxes, as adjusted	<u>11,816</u>	<u>11,519</u>	<u>40,515</u>	<u>38,123</u>
Provision for income taxes, as reported	(8,582)	2,726	(2,755)	8,213
Non-cash, stock-based compensation	744	1,116	2,093	3,266
U.S. governmental inquiries/DPA related	1,873	369	3,371	2,185
Deferred financing fees and transaction costs associated with Convertible Notes Tender Offer	—	—	1,599	—
Restructuring charges	4,574	52	4,574	443
Employment matters ⁽¹⁾	720	—	720	—
Product liability provision	4,740	—	4,740	—
Provision for income taxes, as adjusted	<u>\$ 4,069</u>	<u>\$ 4,263</u>	<u>\$ 14,342</u>	<u>\$ 14,107</u>
Effective tax rate, as adjusted	<u>34.4%</u>	<u>37.0%</u>	<u>35.4%</u>	<u>37.0%</u>
Net income, as adjusted	<u>\$ 7,747</u>	<u>\$ 7,256</u>	<u>\$ 26,173</u>	<u>\$ 24,016</u>

(1) Costs associated with settlement of certain employment matters and the hiring of a new CEO.

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(continued)

	Three Months Ended		Three Months Ended	
	September 30, 2011		September 30, 2010	
	<u>As Reported</u>	<u>As Adjusted</u>	<u>As Reported</u>	<u>As Adjusted</u>
Basic net income	\$ (16,045)	\$ 7,747	\$ 4,650	\$ 7,256
Interest expense on convertible notes	N/A	137	N/A	935
Diluted net income	\$ (16,045)	\$ 7,884	\$ 4,650	\$ 8,191
Basic shares	38,406	38,406	37,935	37,935
Dilutive effect of stock options and restricted shares	—	130	76	76
Dilutive effect of convertible notes	N/A	891	N/A	6,126
Diluted shares	38,406	39,427	38,011	44,137
Net income per share, diluted	<u>\$ (0.42)</u>	<u>\$ 0.20</u>	<u>\$ 0.12</u>	<u>\$ 0.19</u>

	Nine Months Ended		Nine Months Ended	
	September 30, 2011		September 30, 2010	
	<u>As Reported</u>	<u>As Adjusted</u>	<u>As Reported</u>	<u>As Adjusted</u>
Basic net income	\$ (6,306)	\$ 26,173	\$ 8,972	\$ 24,016
Interest expense on convertible notes	N/A	1,066	N/A	2,805
Diluted net income	\$ (6,306)	\$ 27,239	\$ 8,972	\$ 26,821
Basic shares	38,228	38,228	37,748	37,748
Dilutive effect of stock options and restricted shares	—	149	175	175
Dilutive effect of convertible notes	N/A	2,249	N/A	6,126
Diluted shares	38,228	40,626	37,923	44,049
Net income per share, diluted	<u>\$ (0.16)</u>	<u>\$ 0.67</u>	<u>\$ 0.24</u>	<u>\$ 0.61</u>

	Three Months Ended		Nine Months Ended	
	September 30, 2011	September 30, 2010	September 30, 2011	September 30, 2010
Net Income per Diluted Share				
Net (loss) income, as reported, per diluted share	\$ (0.42)	\$ 0.12	\$ (0.16)	\$ 0.24
Interest expense on convertible notes	0.00	0.02	0.03	0.06
Effect of convertible notes on diluted shares	0.01	(0.02)	0.01	(0.03)
Non-cash, stock-based compensation	0.04	0.05	0.11	0.16
Restructuring charges	0.24	0.00	0.23	0.02
Deferred financing fees and transaction costs associated with Convertible Notes Tender Offer	—	—	0.06	—
U.S. governmental inquiries/DPA related	0.08	0.01	0.15	0.17
Employment matters ⁽¹⁾	0.03	—	0.03	—
Product liability	0.22	—	0.21	—
Net income, as adjusted, per diluted share	<u>\$ 0.20</u>	<u>\$ 0.19</u>	<u>\$ 0.67</u>	<u>\$ 0.61</u>

(1) Costs associated with settlement of certain employment matters and the hiring of a new CEO.